Tiziana Life Sciences (TLSA) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Veraxa Biotech (VRXA) over the past year, losing 50.7% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($154.1 million vs $143.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSA | VRXA |
|---|---|---|
| Share price | $1.13 | $1.09 |
| Market cap | $143.80M | $154.13M |
| 1-day change | +2.73% | -9.17% |
| YTD return | -24.16% | -88.75% |
| 1-year return | -50.66% | -88.53% |
| 5-year return | -25.17% | — |
| EPS (TTM) | $-0.16 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.30 | $27.36 |
| 52-week low | $0.76 | $1.04 |
| Distance from 52-week high | -50.87% | -96.02% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +606.19% | — |
| Average volume | 717.23K | 274.75K |
| Shares outstanding | 127.26M | 141.41M |
| Employees | 10 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed VRXA by 37.9 percentage points over the past year.
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
TLSA vs VRXA FAQ
Which is bigger, Tiziana Life Sciences or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $154.13M compared with $143.80M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, TLSA or VRXA?
TLSA returned -50.66% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Tiziana Life Sciences and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.